Cardiovascular Systems Stock News

LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022

Cardiovascular Systems, Inc. (NASDAQ:CSII ) Q3 2022 Earnings Conference Call May 5, 2022 9:00 AM ET Company Participants Jack Nielsen - Vice President, Investor Relations Scott Ward - Chairman, Presid

Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO HOST EARNINGS CONFERENCE CALL ON MAY 4, 2022

Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

Cardiovascular Systems (CSII) said enrollment has begun in a first in-human trial of peripheral everolimus drug-coated balloon ((DCB)) being developed by Chansu Vascular…

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

New York, USA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026 As per DelveInsight analysis, the demand for Peripheral Vascular Devices is increasing due to the rapid rise in cardiovascular and peripheral vascular diseases prevalence, as well as the approval of new and improved products by market players along with the rising frequency of lifestyle disorders such as diabetes and hypertension. DelveInsight''s Peripheral Vascular Devices Market Insights report provides the current and forecast Peripheral Vascular Devices market, upcoming device innovation, individual market shares, challenges, drivers, barriers, and market trends and key Peripheral Vascular Device companies in the market. Key Takeaways from the Peripheral Vascular Devices Market report According to DelveInsight analysis, North America is expected to dominate the Peripheral Vascular Devices market during the forecast period. Key Peripheral Vascular Device companies working in the global market are Medtronic, Boston Scientific Corporation, B.

Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.